Search Results - Brendon L. Neuen

Refine Results
  1. 1
    Heart Failure in Patients with Diabetes and Chronic Kidney Disease: Challenges and Opportunities

    Heart Failure in Patients with Diabetes and Chronic Kidney Disease: Challenges and Opportunities by Kris Vijay, Brendon L. Neuen, Edgar V. Lerma

    Published 2021
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  2. 2
    Empagliflozin in Patients with Chronic Kidney Disease

    Empagliflozin in Patients with Chronic Kidney Disease by Brendon L. Neuen, Robert A. Fletcher, Hiddo J.L. Heerspink

    Published 2023
    Get full text
    Carta
    Save to List
    Saved in:
  3. 3
    Chronic kidney disease and the global NCDs agenda

    Chronic kidney disease and the global NCDs agenda by Brendon L. Neuen, Steven J. Chadban, Alessandro Demaio, David W. Johnson, Vlado Perkovic

    Published 2017
    Get full text Get full text
    Editorial
    Save to List
    Saved in:
  4. 4
    Chronic kidney disease

    Chronic kidney disease by Kamyar Kalantar‐Zadeh, Tazeen H. Jafar, Dorothea Nitsch, Brendon L. Neuen, Vlado Perkovic

    Published 2021
    Get full text
    Revisão
    Save to List
    Saved in:
  5. 5
    Effects of anti-inflammatory agents on clinical outcomes in people with chronic kidney disease: a systematic review and meta-analysis of randomised control trials

    Effects of anti-inflammatory agents on clinical outcomes in people with chronic kidney disease: a systematic review and meta-analysis of randomised control trials by Edward W. Webster, Adam Perkovic, Brendon L. Neuen, Katherine R. Tuttle, Vlado Perkovic

    Published 2025
    Get full text
    Revisão
    Save to List
    Saved in:
  6. 6
    Predictors of Patency after Balloon Angioplasty in Hemodialysis Fistulas: A Systematic Review

    Predictors of Patency after Balloon Angioplasty in Hemodialysis Fistulas: A Systematic Review by Brendon L. Neuen, Ronny Gunnarsson, Angela C Webster, Richard Baer, Jonathan Golledge, Murty L. Mantha

    Published 2014
    Get full text
    Revisão
    Save to List
    Saved in:
  7. 7
    Neutrophil–lymphocyte ratio predicts cardiovascular and all-cause mortality in hemodialysis patients

    Neutrophil–lymphocyte ratio predicts cardiovascular and all-cause mortality in hemodialysis patients by Brendon L. Neuen, Nicole Leather, A.M. Greenwood, Ronny Gunnarsson, Yeoungjee Cho, Murty L. Mantha

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    SGLT2 inhibitors for patients with type 2 diabetes and CKD: a narrative review

    SGLT2 inhibitors for patients with type 2 diabetes and CKD: a narrative review by Merlin C. Thomas, Brendon L. Neuen, Stephen M. Twigg, Mark E. Cooper, Sunil V. Badve

    Published 2023
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  9. 9
    Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes

    Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes by Jingwei Li, Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Brendon L. Neuen, Clare Arnott, Robin Simpson, Richard Oh, Kenneth W. Mahaffey, Hiddo J.L. Heerspink

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta‐analysis

    Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta‐analysis... by Tadashi Toyama, Brendon L. Neuen, Min Jun, Toshiaki Ohkuma, Bruce Neal, Meg Jardine, Hiddo J.L. Heerspink, Muh Geot Wong, Toshiharu Ninomiya, Takashi Wada, Vlado Perkovic

    Published 2019
    Get full text
    Revisão
    Save to List
    Saved in:
  11. 11
    Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE Trials

    Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE Trials by Sheldon W. Tobe, Thomas A. Mavrakanas, Harpreet S. Bajaj, Adeera Levin, Navdeep Tangri, April Slee, Brendon L. Neuen, Vlado Perkovic, Kenneth W. Mahaffey, Wally Rapattoni, Fernando G. Ang

    Published 2024
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Sodium‐Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis

    Sodium‐Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis by Clare Arnott, Qiang Li, Amy Kang, Brendon L. Neuen, Séverine Bompoint, Carolyn S.P. Lam, Anthony Rodgers, Kenneth W. Mahaffey, Christopher P. Cannon, Vlado Perkovic, Meg Jardine, Bruce Neal

    Published 2020
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  13. 13
    Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the <scp>CANVAS</scp> Program and <scp>CREDENCE</scp> trial

    Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the <scp>CANVAS</scp> Program and <scp>CREDENCE</scp> trial by Jennifer Barraclough, Jie Yu, Gemma A. Figtree, Vlado Perkovic, Hiddo J.L. Heerspink, Brendon L. Neuen, Christopher P. Cannon, Kenneth W. Mahaffey, Aletta E. Schutte, Bruce Neal, Clare Arnott

    Published 2022
    Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial

    Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the D... by Akihiko Koshino, Brendon L. Neuen, Niels Jongs, Carol A. Pollock, Peter J. Greasley, Eva-Marie Andersson, Ann Hammarstedt, Cecilia Karlsson, Anna Maria Langkilde, Takashi Wada, Hiddo J.L. Heerspink

    Published 2023
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program

    Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program by Brendon L. Neuen, Toshiaki Ohkuma, Bruce Neal, David R. Matthews, Dick de Zeeuw, Kenneth W. Mahaffey, Greg Fulcher, Qiang Li, Meg Jardine, Richard Oh, Hiddo J.L. Heerspink, Vlado Perkovic

    Published 2019
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program

    Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program by Brendon L. Neuen, Toshiaki Ohkuma, Bruce Neal, David R. Matthews, Dick de Zeeuw, Kenneth W. Mahaffey, Greg Fulcher, Jaime D. Blais, Qiang Li, Meg Jardine, Vlado Perkovic, David C. Wheeler

    Published 2020
    Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS

    Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS by Akihiko Koshino, Meir Schechter, Taha Sen, Priya Vart, Brendon L. Neuen, Bruce Neal, Clare Arnott, Vlado Perkovic, Paul M. Ridker, Katherine R. Tuttle, Michael K. Hansen, Hiddo J.L. Heerspink

    Published 2022
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    Cardiovascular, Kidney and Safety Outcomes with GLP-1 Receptor Agonists Alone and in Combination with SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis

    Cardiovascular, Kidney and Safety Outcomes with GLP-1 Receptor Agonists Alone and in Combination with SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis by Brendon L. Neuen, Robert A. Fletcher, Lauren Heath, Adam Perkovic, Muthiah Vaduganathan, Sunil V. Badve, Katherine R. Tuttle, Richard E. Pratley, Hertzel C. Gerstein, Vlado Perkovic, Hiddo J.L. Heerspink

    Published 2024
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  19. 19
    The effect of canagliflozin on amputation risk in the <scp>CANVAS</scp> program and the <scp>CREDENCE</scp> trial

    The effect of canagliflozin on amputation risk in the <scp>CANVAS</scp> program and the <scp>CREDENCE</scp> trial by Clare Arnott, Yuli Huang, Brendon L. Neuen, Gian Luca Di Tanna, Christopher P. Cannon, Richard Oh, Robert Edwards, Mary Kavalam, Norman Rosenthal, Vlado Perkovic, Meg Jardine, Kenneth W. Mahaffey, Bruce Neal

    Published 2020
    Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis

    SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis by Brendon L. Neuen, T. Kue Young, Hiddo J.L. Heerspink, Bruce Neal, Vlado Perkovic, Laurent Billot, Kenneth W. Mahaffey, David M. Charytan, David C. Wheeler, Clare Arnott, Séverine Bompoint, Adeera Levin, Meg Jardine

    Published 2019
    Get full text
    Revisão
    Save to List
    Saved in:

Search Tools: